Alzheimer Disease

Ongoing Phenserine clinical program expanded

Published in Biotech Business Week, October 13th, 2003

Axonyx, Inc., (AXYX) announced that it intends to provide Alzheimer disease (AD) patients in the ongoing phase IIB and phase III clinical trials the opportunity to receive Phenserine treatment in a formal open label 6-month extension study.

Phenserine is a dual action acetylcholinesterase and beta amyloid precursor protein (B-APP) inhibitor currently in clinical development for the treatment of mild-to-moderate AD.

All patients that have completed the previously announced and ongoing 75 patient phase IIB and the 375 patient phase III clinical trials will be given the opportunity to receive 6 months of Phenserine treatment in an open-label extension...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2003-10-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry